Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/2/?d=1Neue Studien: Europe PMCde<![CDATA[Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a <i>post hoc</i> analysis of a phase-III trial.]]>https://www.psoriasis-news.de/articles.html/1_articles/efficacy-of-vunakizumab-in-patients-with-moderate-to-severe-plaque-psoriasis-across-diverse-disease-features-a-ltigtpost-hocltigt-analysis-of-a-phase-iii-trial-r643/BackgroundThe efficacy of interleukin-17 inhibitors may be impacted by baseline psoriasis features.

Objective

This post hoc analysis aimed to explore the efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis stratified by diverse disease features.

Methods

This post hoc analysis used data from a phase III trial (NCT04839016); 690 patients with moderate-to-severe plaque psoriasis receiving vunakizumab (n = 461) or placebo (n = 229) were included.

Results

The proportions of patients achieving Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and static physician's global assessment (sPGA) 0/1 responses at week (W)12 were significantly higher in the vunakizumab group than in the placebo group, regardless of the duration of psoriasis, PASI score, body surface area (BSA) involvement, and sPGA score. Similarly, at W4 and W8, treatment response rates were higher in the vunakizumab group than in the placebo group, regardless of the above-mentioned features. The same trend was also found at W24. However, treatment responses at W52 were almost not different between patients continuously receiving vunakizumab and those switching from placebo to vunakizumab, regardless of disease duration and disease severity.

Conclusion

Vunakizumab shows satisfactory efficacy in patients with moderate-to-severe plaque psoriasis, regardless of psoriasis duration and severity.

Weiterlesen

]]>643Mon, 29 Jun 2026 08:21:12 +0000Psoriasis, Atopic Dermatitis, Acne, Inverse Psoriasis and Hidradenitis: A Case Report of Multiple Disease in a Same Young Patient.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-atopic-dermatitis-acne-inverse-psoriasis-and-hidradenitis-a-case-report-of-multiple-disease-in-a-same-young-patient-r642/Weiterlesen

]]>642Mon, 29 Jun 2026 08:21:12 +0000Frequency of complex-to-manage, difficult-to-manage and treatment-refractory psoriatic arthritis: applying the 2025 GRAPPA and EULAR definitions in a real-world longitudinal PsA cohort.https://www.psoriasis-news.de/articles.html/1_articles/frequency-of-complex-to-manage-difficult-to-manage-and-treatment-refractory-psoriatic-arthritis-applying-the-2025-grappa-and-eular-definitions-in-a-real-world-longitudinal-psa-cohort-r641/ObjectivesTo determine the frequency and baseline characteristic differences of complex-to-manage (C2M), difficult-to-manage (D2M) and treatment-refractory (TR) psoriatic arthritis (PsA) in a real-world longitudinal cohort, using the recently proposed 2025 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) definitions.

Methods

We analysed data from newly diagnosed, disease-modifying antirheumatic drug-naïve patients with PsA enrolled in the Dutch Southwest Early Psoriatic Arthritis cohort between 2013 and 2023. Patients were classified using the 2025 GRAPPA (C2M, TR) and EULAR (D2M, TR) PsA definitions. Frequencies were calculated for each definition. Time-to-event analyses using Kaplan-Meier methods assessed the timing of definition fulfilment and individual components. Longitudinal differences in patient-reported outcomes (PROs) were assessed using linear mixed-effects models.

Results

Among 885 newly diagnosed patients with PsA, 20% (179/885) fulfilled the GRAPPA-C2M definition, 4.2% (37/885) fulfilled the EULAR-D2M definition, 3.8% (34/885) met the EULAR-TR and 1.2% (11/885) fulfilled the GRAPPA-TR criteria definition during follow-up. Female sex, higher body mass index (BMI), longer symptom duration, presence of enthesitis and greater skin involvement differed with meeting definitions at baseline. Patients classified as GRAPPA-C2M, GRAPPA-TR, EULAR-D2M and EULAR-TR consistently reported worse long-term PROs (Health Assessment Questionnaire-Disability Index scores in C2M (β=0.17, 95% CI 0.10 to 0.24), GRAPPA-TR (β=0.37, 95% CI 0.22 to 0.51), EULAR-D2M (β=0.36, 95% CI 0.20 to 0.48) and EULAR-TR (β=0.40, 95% CI 0.25 to 0.55)).

Conclusions

Approximately 20% of patients with early PsA fulfilled the GRAPPA-C2M criteria, representing the earliest and broadest subgroup, while 4% met EULAR-D2M/EULAR-TR and 1.2% GRAPPA-TR definitions. These latter subgroups were more likely to be female, had higher BMI, greater skin involvement and enthesitis and experienced persistently worse PROs, underscoring the need for tailored management strategies.

Weiterlesen

]]>641Mon, 29 Jun 2026 08:21:12 +0000A Review of Male Genital Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/a-review-of-male-genital-psoriasis-r640/Weiterlesen

]]>640Mon, 29 Jun 2026 08:21:12 +0000Lymphocyte-Platelet and Neutrophil-Platelet Aggregates are Associated with Dysregulated Platelet Inflammatory Pathways in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/lymphocyte-platelet-and-neutrophil-platelet-aggregates-are-associated-with-dysregulated-platelet-inflammatory-pathways-in-psoriasis-r639/BackgroundPsoriasis is a chronic immune-mediated inflammatory disease associated with heightened cardiovascular risk. Platelets are increasingly implicated in this link through their capacity to amplify vascular inflammation and interact with leukocytes. Circulating leukocyte-platelet aggregates are elevated in psoriasis, although the biological significance of these aggregates remains incompletely understood. We investigated whether increased leukocyte-platelet aggregates is associated with alterations in the platelet transcriptomic profile in psoriasis.

Methods

Leukocyte-platelet aggregate levels were compared between psoriasis patients (n = 42) and healthy controls (n = 29). Psoriasis patients were stratified by the cohort median lymphocyte-platelet aggregate (LyPA) or neutrophil-platelet aggregate (NPA) levels into high vs low aggregate groups. Platelet RNA sequencing was then performed to define transcriptomic differences in high-vs low-aggregate psoriasis.

Results

Psoriasis patients (mean age 46; 60% male; 81% Caucasian) had higher LyPA (P = 0.001) and NPA (P = 0.04) compared with healthy controls (mean age 42; 55% male; 69% Caucasian). Platelet RNA sequencing revealed that psoriasis patients with high LyPA or high NPA had downregulation of platelet inflammatory pathways, including interferon, tumor necrosis factor (TNF), IL-8, and IL-6 signaling.

Conclusion

These findings identify inflammatory platelet transcriptomic alterations associated with elevated lymphocyte-platelet and neutrophil-platelet aggregates in psoriasis and motivate further work to define the functional consequences of leukocyte-platelet aggregates in psoriasis.

Weiterlesen

]]>639Mon, 29 Jun 2026 08:21:12 +0000Dual targeting of cutaneous inflammation and vasculopathy via STING-NF-κB blockade underlies the anti-psoriatic efficacy of Yinxie Granules.https://www.psoriasis-news.de/articles.html/1_articles/dual-targeting-of-cutaneous-inflammation-and-vasculopathy-via-sting-nf-%CE%BAb-blockade-underlies-the-anti-psoriatic-efficacy-of-yinxie-granules-r638/Weiterlesen

]]>638Mon, 29 Jun 2026 08:21:12 +0000Musculoskeletal and nail ultrasound findings in children with psoriasis: a case-control study.https://www.psoriasis-news.de/articles.html/1_articles/musculoskeletal-and-nail-ultrasound-findings-in-children-with-psoriasis-a-case-control-study-r632/BackgroundChildren with psoriasis can develop juvenile psoriatic arthritis. Musculoskeletal ultrasound is a helpful imaging modality in the early recognition of joint inflammation. This pilot study aims to describe clinical and subclinical joint and nail abnormalities in children with psoriasis.

Methods

Children with psoriasis and healthy controls underwent ultrasound examination of various joints, entheses, and nails. Using a standard acquisition protocol, images were obtained in both B-mode and PD-mode. Differences between psoriasis and control groups were examined.

Results

Fifteen psoriasis patients who were not on systemic therapy and did not have clinical signs of arthritis and thirteen age- and sex-matched healthy controls were enrolled. While patients with psoriasis demonstrated subclinical synovitis in the finger, knee, and ankle joints more frequently than the control group (p = 0.047), no statistically significant difference was observed in the comparison of each specific joint. PD positivity was detected at the entheses in two patients with psoriasis and at three entheseal sites of two healthy children. Nail ultrasound examination demonstrated significantly thicker nail beds (1.6 vs. 1.4 mm, p < 0.001) and more frequent abnormal nail structure (70% vs. 21.2%, p < 0.001) in the psoriasis group compared to control group while the thickness of the nail plate and nail matrix were similar. Type II nail morphology changes were the most frequently detected type according to the Wortsman classification. Positive PD-mode findings in the nail bed and nail matrix were more common in the control group (both p < 0.001). Among the psoriasis cohort, nails with abnormal exam findings had significantly thicker nail plate (0.4 vs. 0.35 mm, p = 0.003) and nail bed (1.8 vs. 1.6 mm, p = 0.006) measurements compared to nails with normal examination.

Conclusions

Ultrasound is a useful tool for evaluating inflammatory joint and nail findings that may help delineate subclinical joint inflammation in children with psoriasis.

Weiterlesen

]]>632Mon, 25 May 2026 08:01:40 +0000Alkannin ameliorates imiquimod-induced murine psoriasis by targeting MrgprX2-mediated mast cell activation.https://www.psoriasis-news.de/articles.html/1_articles/alkannin-ameliorates-imiquimod-induced-murine-psoriasis-by-targeting-mrgprx2-mediated-mast-cell-activation-r631/Weiterlesen

]]>631Mon, 25 May 2026 08:01:40 +0000Feasibility of Ultrashort Echo Time MR Imaging for the Detection of Subclinical Achilles Enthesitis in Psoriasis and Psoriatic Arthritis.https://www.psoriasis-news.de/articles.html/1_articles/feasibility-of-ultrashort-echo-time-mr-imaging-for-the-detection-of-subclinical-achilles-enthesitis-in-psoriasis-and-psoriatic-arthritis-r630/s) values were significantly elevated in PsO/PsA compared with healthy volunteers. These findings support the feasibility of UTE bicomponent analysis, as a promising tool for evaluating SI and warrant further investigation.

Weiterlesen

]]>630Mon, 25 May 2026 08:01:40 +0000Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.https://www.psoriasis-news.de/articles.html/1_articles/durability-of-response-to-icotrokinra-for-high-impact-site-psoriasis-1-year-iconic-total-findings-r629/Weiterlesen

]]>629Mon, 25 May 2026 08:01:40 +0000Drug-induced psoriasis following sacubitril/valsartan: a case report and literature review.https://www.psoriasis-news.de/articles.html/1_articles/drug-induced-psoriasis-following-sacubitrilvalsartan-a-case-report-and-literature-review-r628/Weiterlesen

]]>628Mon, 25 May 2026 08:01:40 +0000Association of Body Roundness Index, Lipid Accumulation Product, and Triglyceride-Glucose Index With Psoriasis: A Systematic Review of Observational Studies.https://www.psoriasis-news.de/articles.html/1_articles/association-of-body-roundness-index-lipid-accumulation-product-and-triglyceride-glucose-index-with-psoriasis-a-systematic-review-of-observational-studies-r627/Background and aimsLipid dysregulation plays a crucial role in psoriasis pathogenesis and its cardiometabolic comorbidities. Novel anthropometric indices such as Body Roundness Index (BRI), Lipid Accumulation Product (LAP), and Triglyceride-Glucose (TyG) index have been proposed to better reflect underlying metabolic dysfunction and may be associated with psoriasis risk, severity, and related complications. This systematic review evaluates the current evidence on the associations of BRI, LAP, and the TyG index with psoriasis and related clinical outcomes.

Methods

A comprehensive literature search was conducted from inception up to September 2025. Observational studies examining the relationship between BRI, LAP, or TyG index and psoriasis or its clinical outcomes were included. Data synthesis comprised qualitative and descriptive statistical analyses.

Results

Fifteen studies comprising 65,130 participants from diverse countries met the inclusion criteria. Higher LAP was consistently associated with increased psoriasis risk but showed weak or no correlation with disease severity (PASI). All BRI studies, primarily using US National Health and Nutrition Examination Survey data, demonstrated a positive association between BRI and psoriasis risk, with modest predictive ability (AUC 0.56-0.58). TyG index was linked to adverse metabolic and cardiovascular outcomes, fatty liver disease, and all-cause mortality in psoriasis patients, although correlations with PASI were generally non-significant.

Conclusions

BRI, LAP, and TyG index are consistently associated with psoriasis risk and related metabolic and cardiovascular complications, highlighting their potential utility for early risk stratification and holistic management of psoriasis patients. Further prospective studies are warranted to clarify their predictive value for disease severity and long-term outcomes.

Weiterlesen

]]>627Mon, 25 May 2026 08:01:40 +0000Novel post-translational modification learning signature reveals DPP3 promotes progression of psoriasis by enhancing inflammatory activation.https://www.psoriasis-news.de/articles.html/1_articles/novel-post-translational-modification-learning-signature-reveals-dpp3-promotes-progression-of-psoriasis-by-enhancing-inflammatory-activation-r626/Weiterlesen

]]>626Mon, 25 May 2026 08:01:40 +0000Studying the expression levels of LncRNA-MEG3 and miR-147b in the serum of psoriasis patients with and without dyslipidemia.https://www.psoriasis-news.de/articles.html/1_articles/studying-the-expression-levels-of-lncrna-meg3-and-mir-147b-in-the-serum-of-psoriasis-patients-with-and-without-dyslipidemia-r625/Weiterlesen

]]>625Mon, 25 May 2026 08:01:40 +0000Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional studyhttps://www.psoriasis-news.de/articles.html/1_articles/correction-association-between-lifes-essential-8-and-psoriasis-in-us-adults-a-cross-sectional-study-r624/No abstract supplied.

Weiterlesen

]]>624Mon, 25 May 2026 08:01:40 +0000Plaque-Type Psoriasis Induced by Non-Steroidal Aromatase Inhibitor (Letrozole): A Case Serieshttps://www.psoriasis-news.de/articles.html/1_articles/plaque-type-psoriasis-induced-by-non-steroidal-aromatase-inhibitor-letrozole-a-case-series-r623/No abstract supplied.

Weiterlesen

]]>623Mon, 25 May 2026 08:01:40 +0000Puerarin attenuates keratinocyte proliferation and inflammatory responses in psoriasis via downregulating TIMP2 and alleviating endoplasmic reticulum stress.https://www.psoriasis-news.de/articles.html/1_articles/puerarin-attenuates-keratinocyte-proliferation-and-inflammatory-responses-in-psoriasis-via-downregulating-timp2-and-alleviating-endoplasmic-reticulum-stress-r619/Pueraria lobata, exhibits multiple pharmacological activities, but its role in psoriasis remains unclear. The M5-induced HaCaT cell model was used to evaluate the effects of PUE on proliferation, apoptosis, and inflammation. Cell viability, proliferation, and apoptosis were assessed by CCK-8, EdU, and flow cytometry, while cytokine levels were measured by ELISA. TIMP2 and endoplasmic reticulum (ER) stress-related proteins were detected by RT-qPCR and Western blot. A TIMP2 overexpression assay was performed to verify the mechanism. PUE showed no cytotoxicity in HaCaT cells, but significantly inhibited M5-induced proliferation and inflammatory cytokine release while promoting apoptosis. Mechanistically, PUE reduced the expression of TIMP2 and ERS-related proteins, and TIMP2 overexpression partially reversed these effects. PUE alleviates proliferation and inflammation of keratinocytes in association with downregulation of TIMP2 and inhibition of ER stress-related markers, suggesting that the TIMP2-ERS axis may be implicated as a potential therapeutic target in psoriasis.

Supplementary information

The online version contains supplementary material available at 10.1007/s10616-026-00969-x.

Weiterlesen

]]>619Thu, 14 May 2026 18:05:26 +0000Psoriatic arthritis spectrum in children: a multicentre observational study.https://www.psoriasis-news.de/articles.html/1_articles/psoriatic-arthritis-spectrum-in-children-a-multicentre-observational-study-r618/ObjectivesThe aim of this study is to describe characteristics of children with the International League of Associations for Rheumatology (ILAR)-defined juvenile idiopathic arthritis (JPsA) and to assess whether more sensitive and specific criteria for defining JPsA can be identified.

Methods

A retrospective observational multicentre study was conducted including patients with a diagnosis of JPsA according to ILAR criteria. In this population, we identified clusters using as variables the clinical criteria of JPsA according to ILAR and the CASPAR clinical criteria. In addition, we defined as undifferentiated arthritis patients that met the ERA criteria, as defined by ILAR, and presented psoriatic features such as psoriasis or a history of psoriasis or psoriatic arthritis in a first-degree relative.

Results

73 patients were enrolled. Three clinical clusters were found using unsupervised principal component analysis for the patients. Cluster 1 differed significantly for older patients and psoriasis. In contrast, Cluster 2 was mainly characterised by dactylitis and Cluster 3 was defined by family history of psoriasis and a significant prevalence of dactylitis. We also showed a statistically significant presence of familiarity for psoriatic arthritis in Cluster 2. The significance for all parameters evaluated did not change even when we included the patients with undifferentiated arthritis, except for MTX treatment, which was significantly more common in Cluster 2 (p=0.02), and tenosynovitis, also in Cluster 2 (p=0.05). Moreover, we evaluated our cohort by the Vancouver criteria. Combining the ILAR, CASPAR, and Vancouver criteria only two patients remain undifferentiated.

Conclusions

Our study showed three clinical clusters with diverse demographic and clinical characteristics, indicating JPsA heterogeneity. The findings highlight the need to look beyond ILAR criteria for clinical variables, including family history of psoriatic arthritis. The ILAR, CASPAR, and Vancouver criteria improve the diagnosis of paediatric psoriatic spectrum arthritis. This complex disease population needs larger cohorts and clinical data, especially on axial involvement, to better categorisation and treatment.

Weiterlesen

]]>618Thu, 14 May 2026 18:05:26 +0000Gentiopicroside Ameliorates Psoriasis-Like Dermatitis by Modulating Immune Homeostasis and Suppressing NF-κB Activation.https://www.psoriasis-news.de/articles.html/1_articles/gentiopicroside-ameliorates-psoriasis-like-dermatitis-by-modulating-immune-homeostasis-and-suppressing-nf-%CE%BAb-activation-r617/Weiterlesen

]]>617Thu, 14 May 2026 18:05:26 +0000Sociodemographic Factors Associated With Diagnosed Psoriasis in U.S. Adults: Patterns and Trends From NHANES and NHIS, 2003-2024.https://www.psoriasis-news.de/articles.html/1_articles/sociodemographic-factors-associated-with-diagnosed-psoriasis-in-us-adults-patterns-and-trends-from-nhanes-and-nhis-2003-2024-r616/ObjectiveTo quantify sociodemographic differences in the prevalence of diagnosed psoriasis and to evaluate temporal trends in its epidemiologic distribution.

Methods

Data from the 2003-2006 and 2009-2014 National Health and Nutrition Examination Survey and the 2023-2024 National Health Interview Survey were analyzed. Meta-analysis was performed to determine whether age, sex, race/ethnicity, interview language, marital status, BMI, education, income, and health insurance are independently associated with odds of diagnosed psoriasis. Estimates from each survey period were tested for linear trends over time.

Results

The total sample included 53,225 participants. Spanish speakers, compared to English speakers, demonstrated markedly lower prevalence of diagnosed psoriasis (pooled aOR = 0.40, 95% CI = 0.25-0.65), even after adjusting for other sociodemographic factors including race/ethnicity. Other factors independently associated with psoriasis were older age, non-Hispanic White race/ethnicity, and higher BMI (all P < 0.001). No temporal trends in prevalence were found in any sociodemographic subgroup.

Conclusion

This analysis of national data covering an almost 25-year period indicates psoriasis has consistently been one of the most common inflammatory skin diseases with a stable sociodemographic distribution over this time. High rates of potentially undiagnosed psoriasis among vulnerable sociodemographic subgroups may be a persistent issue spanning over 2 decades. Patients with limited English proficiency may have difficulty interacting with the healthcare system, leading to undiagnosed psoriasis. Difficulty of diagnosis in patients with skin of color may also contribute. Given that psoriasis is a condition with systemic effects, including impacts on cardiovascular risk, accurate and timely diagnosis is essential to ensure appropriate clinical management.

Weiterlesen

]]>616Thu, 14 May 2026 18:05:26 +0000Targeting serine/glycine metabolism to attenuate IFN-γ- and IL-22-driven inflammation and hyperproliferation in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/targeting-serineglycine-metabolism-to-attenuate-ifn-%CE%B3-and-il-22-driven-inflammation-and-hyperproliferation-in-psoriasis-r615/Weiterlesen

]]>615Thu, 14 May 2026 18:05:26 +0000Immunohistochemistry Revealed Distinct IL-36γ Localization Among Different Skin Diseases.https://www.psoriasis-news.de/articles.html/1_articles/immunohistochemistry-revealed-distinct-il-36%CE%B3-localization-among-different-skin-diseases-r614/Weiterlesen

]]>614Thu, 14 May 2026 18:05:26 +0000Promoting keratinocyte psoriasiform changes and IL-17RE expression: Potential role of GLT1D1 in linear psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/promoting-keratinocyte-psoriasiform-changes-and-il-17re-expression-potential-role-of-glt1d1-in-linear-psoriasis-r613/BackgroundLinear psoriasis is a rare variant of psoriasis characterized by erythema and scaling along the Blaschko lines. Its pathogenesis remains unknown.

Objective

To investigate the molecular and immunological mechanisms of linear psoriasis through gene mutation analysis and in vitro experiments and identify potential combined therapeutic targets for psoriasis.

Methods

Whole-exome sequencing was performed on linear lesion, clinically normal skin, and peripheral blood from linear psoriasis patient to identify somatic mutations. Candidate gene expression was assessed using public RNA-seq data of linear and classic psoriasis vulgaris, dataset before and after IL-17 antagonist Brodalumab treatment, and single-cell data of recurrent psoriasis lesions. Immunofluorescence staining confirmed gene expression and distribution. In vitro keratinocyte assays evaluated effects on proliferation and inflammation. Based on these findings, the patient received IL-17 antagonist therapy (Ixekizumab).

Results

An increased copy number variant of Glycosyltransferase 1 Domain Containing 1 (GLT1D1), not previously reported, was identified in the epidermis of linear psoriasis. GLT1D1 was highly expressed in both linear psoriasis and classic psoriasis vulgaris, as well as in recurrent lesions and in patients who failed to achieve PASI75 with IL-17 antagonist therapy. In keratinocytes, GLT1D1 overexpression promoted cell proliferation, enhanced proinflammatory cytokine secretion, and activated IL-17 signaling, particularly via IL-17RE upregulation. In imiquimod-induced mouse models, GLT1D1 overexpression aggravated psoriasiform inflammation. Clinical improvement was observed in the patient after treatment with ixekizumab.

Conclusion

GLT1D1, with an abnormally high copy number, may contribute to psoriasiform changes in keratinocytes by promoting proliferation, increasing proinflammatory cytokine secretion, and enhancing IL-17RE expression.

Weiterlesen

]]>613Thu, 14 May 2026 18:05:26 +0000Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study.https://www.psoriasis-news.de/articles.html/1_articles/impact-of-biologic-class-and-treatment-line-on-psoriatic-arthritis-risk-in-psoriasis-a-population-based-cohort-study-r612/BackgroundPatients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence suggests that biologic therapies may differentially influence the development of PsA; however, there are no data on the relative ability of second-line biological therapy to prevent PsA.

Aim

To evaluate the impact of biologic therapy on the risk of incident PsA in patients with PsO with a focus on second-line biologic therapy.

Methods

We identified 2819 patients who initiated biologic therapy for PsO between 2002 and 2022, including Tumor Necrosis Factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, IL-23p19 inhibitors and IL-12/23 inhibitors. The primary outcome was incident PsA. Kaplan-Meier survival analysis and Cox proportional hazards models were used to evaluate arthritis-free survival and HRs for the development of PsA. Risk was assessed separately for first-line and second-line biologic therapy.

Results

Among 2819 patients with PsO initiating first-line biologic therapy, 400 (14.2%) developed PsA. In multivariable Cox regression, first-line anti-IL-23p19 agents were significantly associated with a lower risk of developing PsA compared with TNF inhibitors (HR 0.13; 95% CI 0.02 to 0.96; p=0.045). Among 1246 patients receiving second-line biologics, 125 (10.0%) developed PsA. Notably, in second-line therapy, only IL-17 inhibitors were independently associated with a statistically significant reduction in PsA risk versus TNF inhibitors (HR 0.37; 95% CI 0.16 to 0.85; p=0.019), with trends observed for anti-IL-12/23 (HR 0.14; 95% CI 0.02 to 1.05; p=0.056) and anti-IL-23p19 (HR 0.46; 95% CI 0.20 to 1.07; p=0.070).

Conclusions

This is the first study to evaluate second-line biological therapy in relation to PsA risk. IL-17 inhibitor therapy was significantly associated with a reduced risk of incident PsA compared with TNF inhibitors.

Weiterlesen

]]>612Thu, 14 May 2026 18:05:26 +0000Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study.https://www.psoriasis-news.de/articles.html/1_articles/complete-clearance-of-high-impact-sites-with-risankizumab-in-patients-with-psoriasis-a-2-year-real-world-retrospective-multicenter-cohort-study-r611/ObjectivesPlaque psoriasis frequently involves high-impact anatomical sites such as the scalp, nails, and palmoplantar regions, which are associated with significant functional impairment and reduced quality of life. Evidence on the long-term effectiveness of biologic therapies in these locations in real-world settings remains limited. This study aimed to evaluate the real-world effectiveness and safety outcomes of risankizumab in achieving complete clearance of psoriasis affecting high-impact sites over a 2-year period.

Methods

We conducted a retrospective multicenter cohort study including adult patients with plaque psoriasis who initiated risankizumab between January 2020 and December 2023 across six dermatology centers. Effectiveness was assessed as the proportion of patients achieving complete clearance (Physician Global Assessment score of 0) in scalp, nail, and palmoplantar psoriasis.

Results

Among 459 patients treated with risankizumab, 232 (50.5%) had involvement of at least one high-impact site at baseline. Complete clearance at 2 years was achieved in 72.5% of patients with scalp involvement, 64.7% of those with nail psoriasis, and 52.2% of those with palmoplantar disease. Adverse events were infrequent and not treatment-limiting.

Conclusions

These findings support the effectiveness of risankizumab in high-impact psoriasis sites in real-world clinical practice.

Weiterlesen

]]>611Thu, 14 May 2026 18:05:26 +0000